Efficacy News and Research

RSS
Phase I/II trials of new paratyphoid vaccine begin in Oxford

Phase I/II trials of new paratyphoid vaccine begin in Oxford

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

Eradicating Polio; What's it going to take?

Eradicating Polio; What's it going to take?

Dotmatics, previously Insightful Science, set to transform the future of scientific software and data management

Dotmatics, previously Insightful Science, set to transform the future of scientific software and data management

Effectiveness of CoronaVac, AZD1222, and BNT162b2 vaccine boosters

Effectiveness of CoronaVac, AZD1222, and BNT162b2 vaccine boosters

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

As vaccination coverage increases, SARS-CoV-2 genetic diversity decreases

As vaccination coverage increases, SARS-CoV-2 genetic diversity decreases

ACT-based program is an effective treatment for reducing criminal behavior, study finds

ACT-based program is an effective treatment for reducing criminal behavior, study finds

A potential way for overcoming immunotherapy resistance in patients with mucosal melanomas

A potential way for overcoming immunotherapy resistance in patients with mucosal melanomas

Treating COVID-19 using monoclonal antibodies during pregnancy

Treating COVID-19 using monoclonal antibodies during pregnancy

Study reports increased numbers of SARS-CoV-2-reactive T cells in individuals who were HCoV-reactive

Study reports increased numbers of SARS-CoV-2-reactive T cells in individuals who were HCoV-reactive

World Malaria Day 2022: How the knockdown of P. falciparum RAP01 and RAP21 proteins could lead to novel antimalarial therapeutics

World Malaria Day 2022: How the knockdown of P. falciparum RAP01 and RAP21 proteins could lead to novel antimalarial therapeutics

Anti-SARS-CoV-2 spike antibody levels following COVID-19 BNT162b2 vaccination

Anti-SARS-CoV-2 spike antibody levels following COVID-19 BNT162b2 vaccination

Vaccine effectiveness against symptomatic disease caused by the Omicron and Delta variants in England

Vaccine effectiveness against symptomatic disease caused by the Omicron and Delta variants in England

The challenges of Omicron

The challenges of Omicron

The long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination

The long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination

World Immunization Week 2022: Striving for a Long Life for All with the International Vaccine Institute

World Immunization Week 2022: Striving for a Long Life for All with the International Vaccine Institute

Monoclonal-antibody combination AZD7442 prevents COVID-19

Monoclonal-antibody combination AZD7442 prevents COVID-19

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels

Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.